Hematological Oncology

Published by: Wiley Blackwell  

People

  1. Yahalom
    Yahalom
  2. Zelenetz
    Zelenetz
  3. Hamlin
    Hamlin
  4. Kumar
    Kumar
  5. Moskowitz
    Moskowitz
  6. Noy
    Noy
  7. Horwitz
    Horwitz
  8. Palomba
    Palomba
  9. Salles
    Salles
  10. Schoder
    Schoder

Groups

  1. Center for Hematologic Malignancies (9)
  2. Department of Medicine (9)
  3. Hematologic Malignancies, Division of (9)
  4. Lymphoma (9)
  5. Radiation Oncology, Department of (9)
  6. Survivorship Research (9)
  7. Population Sciences Research Program (6)
  8. Sloan Kettering Institute Postdocs (6)
  9. Epidemiology and Biostatistics (5)
  10. Executive Committee, Center for Hematologic Malignancies (5)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "Joachim Yahalom"
  3. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (9)
Groups
  1. Center for Hematologic Malignancies (9)
  2. Department of Medicine (9)
  3. Hematologic Malignancies, Division of (9)
  4. Lymphoma (9)
  5. Radiation Oncology, Department of (9)
  6. Survivorship Research (9)

More Groups

People
  1. Andrew Zelenetz (9)
  2. Joachim Yahalom (9)
  3. Alison Moskowitz (7)
  4. Anita Kumar (7)
  5. Ariela Noy (7)
  6. David Straus (7)

More People

Years
  1. 2023 (4)
  2. 2021 (1)
  3. 2019 (2)
  4. 2017 (2)
Publishers
  1. Wiley Blackwell (9)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A.; Salles, G.; Yahalom, J.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save

    • Hematological Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 02780232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell